• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland.

作者信息

Snider D E, Rogowski J, Zierski M, Bek E, Long M W

出版信息

Am Rev Respir Dis. 1982 Feb;125(2):265-7. doi: 10.1164/arrd.1982.125.2.265.

DOI:10.1164/arrd.1982.125.2.265
PMID:7065534
Abstract

One hundred nineteen patients 15 to 70 yr of age, all with smear-positive, previously untreated, pulmonary tuberculosis, were treated with a 6-month regimen containing isoniazid and rifampin, supplemented during the initial 2 months with streptomycin and pyrazinamide. The 4 drugs were administered daily in the hospital during the initial 2 months, followed by isoniazid and rifampin administered twice weekly on an outpatient basis during the next 4 months. Adverse reactions to the drugs were seen in 19 patients, but only 6 had toxic reactions requiring withdrawal of drugs for 7 days or more. Three of the toxic reactions were attributed to streptomycin, 2 to rifampin, 1 to isoniazid, and none to pyrazinamide. Eighty-five (71%) of the 119 eligible patients completed treatment. After the first 2 months of therapy, 91% of these patients had negative sputum cultures, and all of them had negative cultures by the end of the third month of treatment. No relapses have occurred among the 84 patients observed for 18 months after therapy was completed.

摘要

相似文献

1
Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland.
Am Rev Respir Dis. 1982 Feb;125(2):265-7. doi: 10.1164/arrd.1982.125.2.265.
2
Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
Am Rev Respir Dis. 1984 Dec;130(6):1091-4. doi: 10.1164/arrd.1984.130.6.1091.
3
Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.对痰涂片阳性肺结核患者采用每周三次、为期6个月的治疗方案,比较2个月、4个月和6个月吡嗪酰胺使用时间的对照试验,包括对异烟肼、利福平及吡嗪酰胺复方制剂的评估。30个月时的结果。香港胸科服务处/英国医学研究委员会
Am Rev Respir Dis. 1991 Apr;143(4 Pt 1):700-6. doi: 10.1164/ajrccm/143.4_Pt_1.700.
4
Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.在一项针对涂片阳性肺结核的三种6个月治疗方案的对照试验中,对异烟肼、利福平及吡嗪酰胺每日联合制剂的评估。新加坡结核病防治所/英国医学研究委员会
Am Rev Respir Dis. 1991 Apr;143(4 Pt 1):707-12. doi: 10.1164/ajrccm/143.4_Pt_1.707.
5
Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.乌干达东南部艾滋病毒血清阳性和艾滋病毒血清阴性患者的结核病化疗与痰菌转阴情况
East Afr Med J. 1999 Jun;76(6):307-13.
6
[Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].含吡嗪酰胺的六个月短程化疗用于肺结核的初始治疗
Kekkaku. 1994 Nov;69(11):671-80.
7
Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.一项关于肺结核治疗中继续期采用三种6个月间歇化疗方案的临床试验的五年随访。新加坡结核病防治所/英国医学研究委员会
Am Rev Respir Dis. 1988 May;137(5):1147-50. doi: 10.1164/ajrccm/137.5.1147.
8
Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment.
Am Rev Respir Dis. 1980 Dec;122(6):879-89. doi: 10.1164/arrd.1980.122.6.879.
9
Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.采用异烟肼、利福平、乙胺丁醇和吡嗪酰胺治疗耐异烟肼结核病6个月。
Int J Tuberc Lung Dis. 2002 Nov;6(11):952-8.
10
Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.肺结核五种短程(4个月)化疗方案的对照临床试验。第4项研究的第二次报告。东非/英国医学研究委员会研究。
Am Rev Respir Dis. 1981 Feb;123(2):165-70. doi: 10.1164/arrd.1981.123.2.165.

引用本文的文献

1
Culture conversion rate at 2 months of treatment according to diagnostic methods among patients with culture-positive pulmonary tuberculosis.根据诊断方法,治疗 2 个月时培养阳性肺结核患者的培养转化率。
PLoS One. 2014 Aug 8;9(8):e103768. doi: 10.1371/journal.pone.0103768. eCollection 2014.
2
Pyrazinamide susceptibility testing of Mycobacterium tuberculosis by high resolution melt analysis.结核分枝杆菌高分辨率熔解曲线分析药敏检测法。
Tuberculosis (Edinb). 2014 Jan;94(1):20-5. doi: 10.1016/j.tube.2013.10.006. Epub 2013 Nov 1.
3
Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.
吡嗪酰胺在一种新型结核病体外杀菌模型中的药代动力学-药效学:一种快速评估新型抗结核药物的范例
Antimicrob Agents Chemother. 2009 Aug;53(8):3197-204. doi: 10.1128/AAC.01681-08. Epub 2009 May 18.
4
Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains.用于快速鉴定耐吡嗪酰胺结核分枝杆菌菌株中pncA基因突变的线性探针检测法的开发与评估
J Clin Microbiol. 2007 Sep;45(9):2802-7. doi: 10.1128/JCM.00352-07. Epub 2007 Jun 27.
5
Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan.台湾地区结核分枝杆菌分离株中吡嗪酰胺活性与pncA基因突变的相关性
Antimicrob Agents Chemother. 2003 Nov;47(11):3672-3. doi: 10.1128/AAC.47.11.3672-3673.2003.
6
Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis.结核分枝杆菌pncA突变体的表型特征分析
Antimicrob Agents Chemother. 2000 Sep;44(9):2291-5. doi: 10.1128/AAC.44.9.2291-2295.2000.
7
Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice.利福拉齐在小鼠结核病长期治疗方案中的评估。
Antimicrob Agents Chemother. 2000 Jun;44(6):1458-62. doi: 10.1128/AAC.44.6.1458-1462.2000.
8
Tuberculosis: 9. Treatment.肺结核:9. 治疗。
CMAJ. 1999 Aug 24;161(4):405-11.
9
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.耐吡嗪酰胺结核分枝杆菌中pncA基因突变的特征分析
Antimicrob Agents Chemother. 1997 Mar;41(3):540-3. doi: 10.1128/AAC.41.3.540.
10
Current and potential treatment of tuberculosis.结核病的现有及潜在治疗方法。
Drugs. 1994 Nov;48(5):689-708. doi: 10.2165/00003495-199448050-00004.